Emerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Emerald Advisers LLC raised its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 8.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,125,744 shares of the company’s stock after purchasing an additional 165,085 shares during the quarter. Travere Therapeutics makes up approximately 1.4% of Emerald Advisers LLC’s holdings, making the stock its 13th largest holding. Emerald Advisers LLC’s holdings in Travere Therapeutics were worth $37,030,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Entropy Technologies LP bought a new stake in shares of Travere Therapeutics during the 4th quarter valued at $214,000. US Bancorp DE increased its position in shares of Travere Therapeutics by 323.4% in the 4th quarter. US Bancorp DE now owns 31,795 shares of the company’s stock valued at $554,000 after buying an additional 24,286 shares in the last quarter. FMR LLC increased its position in shares of Travere Therapeutics by 27.5% in the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after buying an additional 31,772 shares in the last quarter. Two Sigma Advisers LP increased its position in shares of Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after buying an additional 167,100 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after buying an additional 64,744 shares in the last quarter.

Analyst Upgrades and Downgrades

TVTX has been the subject of a number of recent analyst reports. Citigroup upped their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, February 24th. HC Wainwright upped their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Scotiabank upped their price objective on shares of Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.62.

Travere Therapeutics Trading Down 1.4 %

Travere Therapeutics stock opened at $20.53 on Friday. The firm has a 50-day moving average of $20.50 and a 200-day moving average of $18.16. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -5.01 and a beta of 0.75.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. On average, equities analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Sandra Calvin sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This represents a 21.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William E. Rote sold 2,437 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the sale, the senior vice president now directly owns 83,170 shares in the company, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 206,335 shares of company stock valued at $4,453,012. 3.75% of the stock is owned by company insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.